The latest health and social care news and a look at research and development into the treatment of common and rare diseases alike. We also look at the vital changes being made to help deliver effective healthcare through the digital transformation within the NHS.
The Health Tech Alliance explores how looking beyond costs to examine value-based procurement will impact health technology and innovation within the NHS.
The American Heart Association found that young, Black adults are more than twice as likely to die in the first year after a heart transplant - in comparison to non-Black transplant recipients of the same age.
The vaccine roll out gives hope of a return to some form of normality, but current high COVID-19 infection numbers put the success of vaccination programmes at risk. Professor Martin Michaelis and Dr Mark Wass of University of Kent’s School of Biosciences explain why.
A new study by the University of California, Davis has found that a third of Americans are either unlikely or hesitant to get a COVID-19 vaccine when it becomes available.
New clinical trial data shows that the Johnson & Johnson vaccine is able to give 66% protection against COVID in one dose - with an 85% efficiency at the standard double-dose.
Phase Three data from the UK trial shows that Novavax still works powerfully against the UK mutation, with a less intense impact on the South African mutation at 60%.
Engineers at the University of Bath have published a mathematical model that could help clinicians to safely ventilate two COVID patients on one ventilator.
New data from the REACT study finds that the rising infection rate has steadied a little, but there is no "sharp drop in infections" as in the first wave and the R is still high.
AstraZeneca CEO Pascal Soriot spoke to Antonello Guerrera about the ongoing vaccine feud - with the Commission receiving 60% less than expected, raising tense questions about why.
New vaccine data from Israel suggests that the double-dose of Pfizer is performing at the expected rate of 95% efficiency - with the possibility that it is performing even better than that being further investigated.
